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Infection by the human immunodeﬁciency virus type 1 (HIV-1),
the etiological agent of the acquired immunodeﬁciency syndrome
(AIDS), is a worldwide disease characterized by a persistent viral
replication in lymphoid tissues, leading to a profound immunosup-
pression that can culminate in higher susceptibility to opportunistic
infections, tumors and central nervous system degeneration (Steven-
son, 2003). HIV-1 infects and replicates in CD4+ lymphocytes and
monocyte/macrophages, using the CD4 molecule (Dalgleish et al.,
1984) and the chemokine receptors CXCR4 (Feng et al., 1996) or CCR5
(Deng et al., 1996) to penetrate into host cells. A variety of conditions
have been associated with increases in viral load and viral persistence
in HIV-1-infected individuals, such as coinfections (Orenstein et al.,
1997; Toossi et al., 1993; Wahl et al., 1999) and immune activation
(Ortigao-de-Sampaio et al., 1998; Stanley et al., 1996). Immune
activation in HIV-1-infected patients has been recently related tomicrobial translocation from the gut to circulation secondary to an
increased intestinal permeability associated with destruction of the
gut lymphoid tissue (GALT) (Brenchley et al., 2006a; Brenchley et al.,
2006b; Lee et al., 2009). Therefore, activation of the immune cells by
microbial products (such as LPS) and interaction of HIV-1-infected
cells with host molecules can modulate viral replication and inﬂuence
the disease progression.
One of the most complex aspects of AIDS pathogenesis is the
dynamic interplay between HIV-1 and host molecules (Hladik and
McElrath, 2008; Neil et al., 2008). In this context, cytokines and other
inﬂammatory mediators play a pivotal role in the viral replicative
cycle (Alfano et al., 2008; Kedzierska and Crowe, 2001), and a number
of studies support the inﬂuence of these molecules over both the
course of the disease and HIV-1 biology (Alfano et al., 2008; Copeland,
2005; Kedzierska and Crowe, 2001). Pro-inﬂammatory cytokines,
such as Tumor Necrosis Factor (TNF)-α and Interleukin (IL)-6, are
considered to up-regulate HIV-1 replication, whereas certain anti-
inﬂammatory cytokines, such as type 1 Interferon (IFN), IL-10 and IL-
27, may diminish viral replication (Alfano et al., 2008; Kedzierska and
Crowe, 2001). Some cytokines are also capable of interfering in the
HIV-1 replication by means of modulation of cell restriction factors to
the virus. For example, production or activation of the proteins of the
APOBEC family and recently described Tetherin are regulated by IL-2,
Fig. 1. HIV-1-infected patients present higher plasma levels of MIF relative to
uninfected individuals. Plasmas from HIV-1-infected individuals (HIV-1 pos), and
from healthy volunteers (control plasmas; HIV-1 neg) were assessed for MIF
concentrations by ELISA. Bars represent means±SEM of 10 healthy volunteers (HIV-
1 neg) or 30 HIV-1-infected patients (HIV-1 pos). ⁎pb0.0001.
32 E.G. Regis et al. / Virology 399 (2010) 31–38IL-7, IL-15 and IFN-α (Neil et al., 2008; Stopak et al., 2007; Varthakavi
et al., 2008).
Macrophage migration inhibitory factor (MIF) is an upstream
activator of innate immunity, it is present pre-formed in many cell
types and it is endowed with both enzymatic and receptor binding
properties (Bernhagen et al., 2007; Calandra and Roger, 2003; Leng et
al., 2003). MIF lacks a signal sequence and it is secreted by a
specialized pathway that is dependent of ATP-binding cassette (ABC)
transporters, speciﬁcally from the family ABCA1 (Flieger et al., 2003).
Another unique characteristic of MIF is the fact that it binds and
activates a multi-component receptor complex comprising CD74,
CD44, and the chemokine receptors CXCR2 and CXCR4 (Bernhagen et
al., 2007; Calandra and Roger, 2003; Shi et al., 2006). MIF promotes
the release of a number of pro-inﬂammatory cytokines, such as TNF-
α, IL-6 and Prostaglandin E2 (PGE2) (Calandra and Roger, 2003).
Elevated serum levels of MIF have been detected in many infectious
and inﬂammatory diseases, such as reumathoid arthritis, arthero-
sclerosis (Ayoub et al., 2008), sepsis (Bozza et al., 2004; Bozza et al.,
1999; Emonts et al., 2007), West Nile Virus (Arjona et al., 2007) and
others (Calandra and Roger, 2003; Hoi et al., 2007). Moreover, MIF has
been implicated in the worsening of some pathological conditions,
and neutralization of this cytokine ameliorates the disease clinical
course (Amano et al., 2007; Bozza et al., 2004; Calandra et al., 2000;
Chen et al., 2006; Gando et al., 2007; Ichiyama et al., 2004; Meazza
et al., 2002).
Since there are no studies addressing the role of MIF in HIV-1
infection and its ability to modulate HIV-1 replication, we measured
the levels of this cytokine in the plasma of HIV-1-infected patients and
investigated whether it could inﬂuence HIV-1 replication in human
primary peripheral blood mononuclear cells (PBMCs). Here, we show
for the ﬁrst time that plasma levels of MIF are elevated in HIV-1-
infected individuals, PBMCs release MIF upon HIV-1 infection, and
that MIF secretion contributes to viral replication.
Results
HIV-1-infected patients present high plasma levels of MIF
HIV-1 infection increases the secretion of many cytokines in vitro
and in vivo (Kedzierska and Crowe, 2001), and enhancement of MIF
production has been detected either in the sera of patients or at the
site of some inﬂammatory and infectious diseases (Awandare et al.,
2007; He et al., 2006). Also, it is already known that viral infections,
such as the dengue and West Nile virus infection, can up-regulate
serum levels of MIF (Arjona et al., 2007; Chen et al., 2006). Thus, we
hypothesized that a similar phenomenon could be occurring in HIV-1-
infected individuals, and we ﬁrst examined whether these patients
would present higher plasma levels of MIF relative to uninfected
individuals. We selected a group of HIV-1-infected individuals
(n=30) and a control group comprised of healthy volunteers
(n=10). Plasma was collected from these individuals and the levels
of MIF were investigated by ELISA. It was found that HIV-1-infected
individuals presented plasma concentrations of MIF up to 25 times
higher than the control group (Fig. 1). We found no correlation
between plasma viral loads and MIF levels (data not shown).
MIF is secreted by primary PBMCs infected with HIV-1 in vitro
Based on the ﬁndings that some viral infections can up-regulate
MIF secretion in vitro, such as West Nile virus, human Cytomegalo-
virus (CMV) and Inﬂuenza A infections (Arjona et al., 2007; Arndt et
al., 2002; Bacher et al., 2002), and in order to understand if HIV-1
infection itself could be contributing for these higher levels of MIF in
the plasma of infected patients, we infected human primary PBMCs
and macrophages and examined whether HIV-1 infection would
induce these cells to secrete MIF. PBMCs were infected with either anR5-tropic or an X4-tropic HIV-1 isolate and MIF secretion and viral
replication were evaluated 4 and 7 days after infection. We detected
that, infection with HIV-1 R5-tropic isolate doubled the release of MIF
by these cells relative to MIF secretion by PBMCs (Fig. 2A and B). Of
note, there was no signiﬁcant increase in secreted MIF at 4 days of
infection (data not shown), suggesting that MIF release may follow a
similar kinetics to virus replication in PBMC, since HIV-1 replication
usually peaks about 7 days after infection of these cells. The increment
in MIF secretion by HIV-1-infected PBMC is not restricted by the
phenotype of the HIV-1 isolate, as evidenced by the fact that the
infection by an X4-tropic strain also increased MIF secretion, as
measured 7 days after infection (Fig. 2C). We also measured MIF
secretion by HIV-1-infected monocyted-derived macrophages and,
curiously, HIV-1 infection of macrophages did not alter the secretion
of basal levels of MIF (Fig. 2D), as observed in two time points (7 and
14 days after infection), suggesting a phenomenon restricted to
PBMCs.
HIV-1 gp120 also induces MIF secretion by PBMC
Based on our ﬁndings that the increment of MIF secretion was
signiﬁcant 7 days after infection, at the same time point when
elevated amounts of HIV-1 production are also detected, we
hypothesized that the HIV-1 virion per se, or HIV-1 components
could induce direct secretion of MIF through interaction with infected
or uninfected PBMCs in culture. In fact, it has been described that viral
components can accumulate in cultures of HIV-1 infected PBMCs, such
as gp120 (Zhang et al., 1997). Based on the ability of HIV-1 envelope-
derived gp120 protein to trigger the secretion of a variety of cytokines
and that gp120 can be detected in serum of HIV-1+ patients
(Capobianchi, 1996; Klasse and Moore, 2004), we exposed uninfected
PBMCs to a concentration of soluble recombinant BaL gp120 (r gp120)
protein previously known to induce cytokine secretion (5 μg/mL) for
16 h (Schols and De Clercq, 1996). We observed that r gp120
promoted MIF secretion by treated PBMC (Fig. 2E) at approximately
50% more than untreated cells, suggesting that viral components can
contribute to the enhanced MIF release by HIV-1-infected PBMC
cultures.
HIV-1 infection stimulates MIF release through ABCA1 transporters
The release ofMIF upon stimulation bymicrobial components such
as lipopolysaccharide (LPS) has been shown to be dependent on the
ABCA1-family of the ATP-binding cassette (ABC) transporters (Flieger
et al., 2003). Thus, it was of interest to examine whether ABC trans-
porters mediate the MIF release promoted by an infectious agent such
as HIV-1. Accordingly, cells were pre-treated with probenecid (10 μM,
Fig. 2. HIV-1 infection and HIV-1 gp120 induce MIF release by PBMCs. (A) PBMCs were infected by an R5-tropic HIV-1 isolate (Ba-L), and after 7 days MIF contents were evaluated in
the culture supernatants by ELISA (⁎pb0.04). Individual values and medians are represented for each group. (B) Lines show individual MIF release in the uninfected and in HIV-1-
infected PBMC depicted in panel A. (C) MIF contents in culture supernatants of PBMCs infected by an X4-tropic HIV-1 isolate (Tybe) (⁎pb0.04). Mean of MIF values by cells cultured
only with medium (Nill): 757.8 pg/mL. (D) Macrophages were infected by the HIV-1 isolate Ba-L and MIF release was assessed by ELISA at 7 (7d) and 14 (14d) days after infection.
Individual values andmedians are represented for each group. (E) Uninfected PBMCs were exposed to recombinant HIV-1 envelope protein gp120 (5 μg/mL) derived from the HIV-1
isolate Ba-L, and MIF secretion was evaluated in culture supernatants by ELISA after 16 h (⁎pb0.006). Mean of MIF values by cells cultured only with medium (Nill): 427 pg/mL. In
(C) and (E) bars show means±SEM for 3 and 5 different donors, respectively, and all experiments were done in triplicates per donor.
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applied to infected cells. MIF release was measured at day 7 post-
infection. Probenecid treatment resulted in a reduction of MIF sec-
retion secondary to HIV-1 infection (Fig. 3), which is consistent with
the notion that the HIV-1-induced MIF release is dependent of ABCA1
transporters.Immunoneutralization of secreted MIF diminishes HIV-1 replication
Based on the preceeding result that HIV-1 infection induces MIF
secretion and to provide evidence for the role of MIF in HIV-1
replication, HIV-1-infected PBMCs were treated with neutralizing
anti-MIF polyclonal antibodies immediately after infection, and viral
Fig. 3.MIF release upon HIV-1 infection is dependent of ABC transporters. PBMCs were
treated with probenecid (Prob; 10 μM, 45 min), then infected or not by an R5-tropic
HIV-1 isolate (BaL), and probenecid was re-applied. MIF contents were measured by
ELISA in culture supernatants 7 days after infection (⁎pb0.0002; ⁎⁎pb0.004). Mean of
MIF values by HIV-1-infected cells cultured only with medium (Nill): 1.6 ng/mL. Data
represent means±SEM for 3 different donors done in triplicates.
Fig. 5. MIF addition exacerbates HIV-1 replication. (A) PBMCs were infected by an R5-
tropic HIV-1 isolate (Ba-L), and treated with rhMIF at indicated concentrations. HIV-1
replicationwasmeasured after 7 days by a p24 Ag ELISA in culture supernatants (12 ng/
mL, ⁎pb0.009; 25 ng/mL, ⁎⁎pb0.03, both relative to untreated cells). Mean of p24
values by HIV-1-infected cells cultured only with medium (Nill): 123 ng/mL; (B)
PBMCs were infected by an X4-tropic HIV-1 (Tybe) and exposed to rhMIF (25 ng/mL).
Viral replication was measured 7 days after infection, as described (⁎pb0.04). Mean of
p24 values by HIV-1-infected cells cultured only with medium (Nill): 73 ng/mL. Data
represent means±SEM for 3 (6 ng/mL), 5 (12 ng/mL) and 9 (25 ng/mL) (A), or 5 (B)
different donors, done in triplicates.
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tralization reduced HIV-1 replication by approximately 40% (Fig. 4),
indicating that MIF inhibition down-regulates HIV-1 replication. This
result suggests that MIF, similar to other pro-inﬂammatory cytokines,
can promote HIV-1 replication in primary HIV-1-infected cells (Kinter
et al., 2000).
Addition of rhMIF to HIV-1-infected PBMCs enhances viral replication
Since immunoneutralization of MIF decreased HIV-1 replication,
we next asked whether the addition of rhMIF could augment viral
replication. Based on the observation that MIF can be detected at
concentrations reaching 25 ng/mL in plasma of HIV-1-infected
patients, we added rhMIF (obtained as described in Bernhagen et
al., 1994) to HIV-1-infected PBMCs just after the infection, and
measured viral replication after 7 days. We found that MIF
signiﬁcantly enhanced HIV-1 replication of a R5-tropic isolate at
doses of 12 and 25 ng/mL, when compared to untreated HIV-1
infected cells (Fig. 5A). MIF also exacerbated the viral replication of an
X4-tropic isolate (Fig. 5B), indicating that the ability of MIF to enhance
viral replication is independent of viral phenotype.Fig. 4.MIF neutralization diminishes HIV-1 replication. PBMCs were infected by an R5-
tropic HIV-1 isolate (BaL) and treated with anti-human MIF polyclonal antibodies
(20 μg/mL) or isotype control. Viral replication was measured after 7 days in culture
supernatants by ELISA (⁎pb0.0001). Mean of p24 values by HIV-1-infected cells
cultured only with medium (Nill): 147 ng/mL. Data represent means±SEM for 5
different donors, done in triplicates.The rhMIF support HIV-1 transcription from LTR
Next, we addressed whether MIF could stimulate viral replication
via induction of HIV-1 transcription from LTR. For this purpose, we
added rhMIF to cultures of a Jurkat CD4+ T derivative cell line (1G5)Fig. 6. rhMIF promotes HIV-1 transcription from LTR. CD4+ T Jurkat derivative cell
lineage (1G5) containing stably transfection of luciferase under control of HIV-1 LTR
was left untreated (control) or treated with PHA (2 μg/mL), Tat (100 ng/mL) or MIF
(25 ng/mL). After 20 h, cells were washed and lysed for luminescence evaluation. Bars
represent one representative of 3 independent experiments with similar results.
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system, Luciferase expression is controlled by transcription from LTR,
and a quantitative analysis of transcription is possible through
luminescence signal emitted by Luciferase (Aguilar-Cordova et al.,
1994). As depicted in Fig. 6, exogenous treatment with 25 ng/mL of
rhMIF increased the transcription fromHIV-1 LTR, suggesting that MIF
drives a biochemical signaling pathway which culminates on HIV-1
transcription. As positive controls, we used PHA stimulation, as well as
HIV1 Tat protein, once this cell lineage was selected for high
responsiveness to these molecules. Taken together, these results
indicate that rhMIF augments HIV-1 replication via induction of direct
HIV-1 transcription.
Discussion
Macrophage migration inhibitory factor (MIF) exhibits a variety of
physiological activities, including enzymatic activity and the property
of being released by the pituitary upon stress situations (Bernhagen et
al., 1994; Calandra and Roger, 2003; Larson and Horak, 2006). This
cytokine has also been implicated in many inﬂammatory and
infectious diseases, such as sepsis and rheumatoid arthritis, to name
a few, and in many of these conditions elevated levels of MIF in the
circulation were found, and MIF neutralization led to amelioration of
the targeted pathology (Javeed and Zhao, 2008).
HIV-1 infection is known to be profoundly regulated by immune
molecules such as cytokines and others soluble factors, that have been
described to modulate HIV-1 replication, and which levels are
commonly found altered in plasma of HIV-1-infected patients.
Therefore, cytokines have been considered pivotal players in the
pathogenesis of HIV-1 infection; they both balance the immune
response and promote or inhibit virus replication (Alfano et al., 2008;
Kedzierska and Crowe, 2001).
Although the role of cytokines in HIV-1 infection and pathogenesis
has largely been explored, there are no reports, so far, about the
participation of MIF in this condition. BecauseMIF can activate several
signaling pathways which can ultimately facilitate HIV-1 replication,
such as activation of the transcription factor NF-κB, PGE2 induction
and TNF-α secretion (Amin et al., 2006; Donnelly et al., 1997; Mitchell
et al., 2002), we decided to analyze whether MIF could also be
involved in HIV-1 biology, uncovering it as an upstream factor
contributing to the delicate balance of the interaction between host
and pathogen in the course of this infection. Our ﬁndings constitute
the ﬁrst report that MIF is present in elevated concentrations in the
plasma of HIV-1-infected individuals and that MIF is secreted by HIV-
1-infected cells or by an HIV-1 component. In addition, our study is
the ﬁrst one to describe secretion of MIF due to a retrovirus infection
in humans. Also, we show here that MIF is an up-regulator of HIV-1
replication in vitro, suggesting a novel role for this cytokine in the
pathogenesis of HIV-1 infection, and that a continuous MIF release by
HIV-1-infected cells can contribute to viral loads and to accelerate
progression to AIDS.
First, we investigated if MIF concentrations were elevated in
the plasma of individuals infected by HIV-1, and we found that in
these patients, levels of MIF were much higher (up to 25 times)
than in uninfected individuals. Although there was no positive
correlation between plasma viral loads and MIF levels (data not
shown), this ﬁnding strongly suggests that HIV-1 infection could
be responsible for augmenting levels of MIF in vivo. At that point,
we could not determine the main source of MIF, whether from
HIV-1-infected cells or infected and uninfected cells exposed to
HIV-1 antigens (e.g., gp120), or even microbial products translo-
cated from the gut (Brenchley et al., 2006a). However, we could
suggest that the amount of circulating virus is not the only factor
triggering MIF release.
To assess if HIV-1-infection could be an event capable of inducing
MIF release, we infected PBMC with both an R5 or an X4-tropic strainof HIV-1. We observed that both phenotypes elicited MIF secretion in
culture, and that infection with an X4-tropic isolate of HIV-1 resulted
in amore pronouncedMIF secretion than the onemediated by the R5-
virus. One explanation for this difference could be the fact that the
expression of CXCR4 on cell membranes is more elevated than CCR5,
which, in ultimate analysis could result in a higher number of infected
cells in vitro and, thus, more cells releasing MIF. Since it has been
reported that in nearly 50% of AIDS patients there is a shift in the viral
co-receptor usage from R5 variants to X4-tropic HIV-1 isolates
(Connor et al., 1997) our ﬁndings suggest that patients harboring
both phenotypes of HIV-1 variants may have two simultaneous
signals for MIF release during the late phases of HIV-1 infection, and
that elevated levels of MIF may be detected in infected patients
regardless of the harbored viral phenotype.
The augmentation of MIF release secondary to HIV-1 infection,
only 7 days after infection might suggest that induction of MIF
secretion requires a peak in the viral replication, or even an
accumulation of some viral component in the culture. To address
this possibility, we treated uninfected cells with HIV-1 gp120 derived
from a R5-tropic strain (Ba-L isolate) and observed a signiﬁcant,
although slight, increase inMIF release after 16h of treatment, showing
that an HIV-1molecule could also induceMIF secretion, although it did
not appear to be the main factor inducing elevated amounts of MIF
release in infected cultures. Certainly, a replicating virus is a more
powerful inducer forMIF release than a soluble glycoprotein, through a
mechanism not yet described. Taking in account that gp120 circulates
in AIDS patients (Chiodi et al., 1987), this viral protein may contribute
to increasing systemic MIF levels as we describe here. Since MIF
secretion can be induced by a variety of endogenous/exogenous
stimuli (Calandra and Roger, 2003), we understand that it is very
difﬁcult to determine the real nature of MIF release in vivo. For an
unknown reason, macrophages did not release greater amounts of MIF
secondary toHIV-1 infection, despite the fact that macrophages are an
important source of MIF (Calandra et al., 1994), suggesting that this
phenomenon is probably restricted by cell type.
It has already been shown that MIF is released after microbial
stimulation, and LPS from gram-negative bacteria is one of the
most potent MIF inducers (Bernhagen et al., 1994; Calandra and
Roger, 2003). MIF release secondary to LPS stimulation is depen-
dent on ABC transporters, as shown by the fact that probenecid, an
inhibitor of the ABCA1 family of the ABC transporters, blocks MIF
secreted upon LPS stimulation (Flieger et al., 2003). The ABCA1
transporter is considered as a major factor responsible for MIF
release, and this cytokine is constitutively expressed and stored in
intracellular pools (Calandra and Roger, 2003). To investigate if the
MIF released by HIV-1 stimulation was also exported from the cells
by means of ABCA1 transporters, we treated HIV-1-infected PBMC
with probenecid and evaluated MIF contents. We found that treat-
ment with probenecid decreased MIF liberation, indicating that the
MIF release upon HIV-1 infection needs the activation of ABCA1
transporters.
The immunoneutralization of MIF in HIV-1-infected cultures
revealed the importance of this molecule in viral replication. Addition
of anti-MIF antibodies in the cell cultures resulted in diminished viral
replication, implying a direct relation between MIF and HIV-1. The
association of MIF with HIV-1 was strengthened by the ﬁnding that
addition of rhMIF to HIV-1-infected cultures led to an augmentation of
viral replication by either R5 or X4-tropic isolates. It is important to
mention that rhMIF favored HIV-1 replication when this cytokine was
added at the same dose (25 ng/mL) observed in HIV-1 plasma
patients, suggesting that this MIF concentration could up-regulate
HIV-1 production in vivo.
Based on our results shown in Fig. 6, we could suggest that
exposure to MIF elicits HIV-1 transcription from LTR, thus favoring
viral replication. It has been demonstrated that MIF triggers a sig-
naling pathway that culminates in activation of the three transcription
36 E.G. Regis et al. / Virology 399 (2010) 31–38factors AP-1, ETS and NF-κB (Amin et al., 2006; Binsky et al., 2007;
Calandra and Roger, 2003; Gore et al., 2008; Kleemann et al., 2000;
Toh et al., 2006) for which HIV-1 LTR contains binding sites (Copeland,
2005). In this context, cytokines can contribute to HIV-1 production
via activation of LTR by positive transcription regulators. For instance,
TNF-α is dependent on NF-κB to drive HIV-1 transcription mediated
by LTR (Duh et al., 1989; Munoz-Fernandez et al., 1997). In addition,
IL-10 cooperates with TNF-α to enhance the binding of AP-1 and
NF-κB to the LTR in cells of the monocyte/macrophage lineage
(Finnegan et al., 1996). Thus, it is plausible to speculate that HIV-1
transcription stimulated by MIF from HIV-1 LTR encompasses
activation and binding of AP-1, ETS and NF-κB to HIV-1 LTR.
Taken together, our results suggest a positive, re-entrant pathway
for the establishment of HIV-1 in the host whereby viral infection of
cells triggers MIF release, which then augments HIV-1 replication.
Because this study was entirely performed in primary cells (except
for data presented in Fig. 6), our results might resemble what is
occurring in HIV-1-infected tissues. Thus, MIF may be acting as a
detrimental molecule to HIV-1-infected individuals, favoring high
viral replication, even supporting viral persistence. Because AIDS
patients succumb to opportunistic pathogens and MIF is secreted
during the course of a great diversity of infections (Baugh and Bucala,
2002), high levels of MIF induced by co-pathogens could augment
HIV-1 replication and contribute to disease progression. Also, it has
recently been shown that microbial translocation from the gut to the
circulation is enhanced in HIV-1-infected individuals and plays a
critical role on chronic immune activation and HIV-1 pathogenesis
(Brenchley et al., 2006b). One of the most common translocated
microbial products, the bacterial LPS, is a strong inducer of MIF
secretion (Calandra and Roger, 2003), can be found in the serum of
HIV-1-infected individuals (Brenchley et al., 2006b) and could be
contributing to higher levels of MIF in the circulation of HIV-1-
infected individuals, thus, favoring viral replication as well. The
precise mechanisms whereby MIF promotes HIV-1 replication is
unknown, but further studies can enlighten this particular issue and
potentially point to MIF as a target molecule for anti-HIV-1 therapy.
Materials and methods
HIV-1 isolates
Assays of PBMC infection were performed with the monocyto-
tropic, CCR5-dependent isolate HIV-1Ba-L and with the CXCR4-
dependent isolate HIV-1Tybe, which were donated to us by the NIH
AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH (Bethesda, MD). Both isolates were expanded in
phytohemagglutinin-activated PBMCs, as described elsewhere (Lima
et al., 2002).
Reagents and ELISA kits
Recombinant human MIF (rhMIF) was obtained as previously
described (Bernhagen et al., 1994); anti-MIF polyclonal antibodies
and goat IgG were purchased from R&D Systems (Minneapolis, MN);
the ABC transporters inhibitor probenecid was obtained from Sigma-
Aldrich (MO, EUA). The recombinant HIV-1Ba-L gp120 and the
recombinant HIV-1 Tat were donated to us by the NIH AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH
(Bethesda, MD). MIF concentration in cell culture supernatants and
in plasma samples was measured by a commercial ELISA kit (R&D
Systems), following manufacturer's instructions.
Acquisition of plasma and assessment of viremia
Plasma of HIV-1 infected and normal individuals were obtained by
venopuncture following collection of informed consent and accordingto FIOCRUZ Institutional Ethics Committee. HIV-1-plasma viral loads
weremeasured using the branched-DNA Versant HIV-1 RNA 3.0 Assay
(lower limit of detection 50 copies HIV RNA/mL; Siemens Healthcare
Diagnostics Inc., NY), according to the manufacturer's instructions.
We selected 10 patients with undetectable viral load (b50 copies HIV
RNA/mL), 10 with viral load between 1000 and 10,000 copies HIV
RNA/mL, and 10 with viral load between 50,000 and 500,000 HIV
RNA/mL. At themoment of plasma collection, HIV-1 patientswere not
under anti-retroviral treatment and did not present clinical signs of
co-infections.
Cells
PBMCs from healthy donors were obtained by density gradient
centrifugation (Hystopaque, Sigma) from buffy coat preparations.
PBMCs were resuspended in RPMI 1640 (LGC Bio, São Paulo, SP,
Brazil) supplemented with 10% heat-inactivated fetal bovine
serum (FBS, Hyclone, Logan, UT), penicillin (100 U/mL), strepto-
mycin (100 g/mL), 2 mM glutamine and 10 mM HEPES, stimu-
lated with 5 μg/mL of phytohemagglutinin (PHA, Sigma) during
2–3 days, and further maintained in culture medium containing
5 U/mL of recombinant human Interleukin-2 (Sigma). Human
monocyte-derived macrophages (MDM) were obtained from PBMCs
by adherence onto plastic plates. Brieﬂy, 1.5×106 PBMCs were
plated onto 48-well Plates (Nalge Nunc) in DMEM containing
10% human serum (Sigma) and penicillin- streptomycin (Sigma).
Cells were maintained at 37 °C in 5% CO2 for 6–7 days for mono-
cyte differentiation into macrophages. Non-adherent cells were
washed out, and macrophages were maintained in DMEM with
10% human serum. Macrophage purity was N90%, as determined
by ﬂow cytometry (FACScan; Becton Dickinson) analysis using
anti-CD3 (PharMingen) and anti-CD14 (PharMingen) monoclonal
antibodies.
HIV-1 infection
PBMCs were infected with either the HIV-1 R5-isolate Ba-L or the
X4-isolate Tybe, using 5 to 10 ng/mL of p24 antigen. After a 2-
h incubation, cells were washed to remove excess virus, and culture
medium was added back to infected PBMC. HIV-1 replication was
evaluated in cell culture supernatants by a commercial ELISA kit,
according to manufacturer's instructions (ZeptoMetrix Co., NY).
Macrophages were infected with HIV-1 R5-isolate Ba-L by exposing
them overnight to viral suspensions containing 5 to 10 ng/mL of p24
antigen. Thus, non-internalized viruses were removed by washing,
and cell monolayers were replenished with fresh medium. HIV-1
production and MIF secretion were measured in cell culture super-
natants as described above.
Effect of MIF on HIV-1 replication
To address the role of MIF in HIV-1 replication, HIV-1-infected
PBMCs were distributed in 96-well culture plates (2×105/well/
200 μL) and treated either with rhMIF, anti-MIF antibodies (or isotype
control; R&D Systems) immediately after cell infection. Cells were
maintained in culture for different time-points, and HIV-1 replication
was measured as described above.
Inhibition of ABC transporters
To inhibit the functioning of ABC transporters, PBMCswere treated
for 45 min with probenecid (10 μM) prior to HIV-1 infection. After
infection, probenecid was added back to cultures, at the same
concentration, for the entire period of the experiment (7 days),
when cell culture supernatants were collected for quantiﬁcation of
MIF production and HIV-1 replication.
37E.G. Regis et al. / Virology 399 (2010) 31–38Treatment of PBMC with recombinant HIV-1 gp120
Uninfected PBMCs were treated with recombinant HIV-1 gp120
derived from the R5-tropic HIV-1 BaL isolate (5 μg/mL) for 16 h; then,
cell culture supernatants were collected for evaluation of MIF release.
Evaluation of transcription from LTR
CD4+ T Jurkat derivative cell line (1G5) containing stably
transfection of luciferase under control of HIV-1 LTR was obtained
from NIH AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH (Bethesda, MD)/Dr Estuardo Aguilar-Cordova and Dr
John Belmont. For evaluation of transcription fromHIV-1 LTR, 106 1G5
cells were plated in the absence of stimulus or in the presence of MIF,
Tat (100 ng/mL) or PHA (2 μg/mL) for 18 h at 37 °C/5% CO2. After this
time period, cells were collected, washed twice with PBS and
processed according Luciferase Detection Kit (Promega, WI). The
luminescence was evaluated on a TD-20/20 luminometer (Turner
Designs), following instructions provided by the manufacturer of
the kit.
Statistical analysis
All results presented in this study were prepared using Graphpad
Prism v4.0 software (San Diego, CA). Statistical analysis calculation
was performed using the same software, and the comparisons
between values were considered signiﬁcantly different when the p
value was minor than 0.05 using Student's t test.
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